Pre-exposure prophylaxis (PrEP) is an effective but understudied tool for preventing HIV among women who inject drugs (WWID). This article is the first to explore WWID’s rationale for PrEP initiation (or refusal) in a real-world setting. Purposive sampling was used to recruit 25 WWID, participating in a PrEP demonstration project operating within a syringe services program, based on whether they initiated or declined PrEP care. Content analysis of qualitative interviews was used to explore decisions to initiate PrEP (or not). We found that WWID view HIV as severe, perceive themselves to be susceptible to HIV, and believe PrEP is beneficial for HIV prevention. For some, however, real and perceived barriers outweighed benefits, leading to decisions not to initiate PrEP. Barriers included HIV stigma, fear of side effects, and needing assurance that PrEP care will be available long-term. Despite viewing PrEP as an important HIV prevention tool, not all WWID who were offered PrEP initiated it. For these women, supports to buffer perceived barriers to initiation and access to post-exposure prophylaxis may be warranted. For women who initiate, it is possible that adherence will wane if perceived risk does not remain high. Research to understand PrEP persistence is needed.
This is a preview of subscription content, access via your institution.
Buy single article
Instant access to the full article PDF.
Tax calculation will be finalised during checkout.
Auerbach, J. D., Kinsky, S., Brown, G., & Charles, V. (2015). Knowledge, attitudes, and likelihood of Pre-Exposure Prophylaxis (PrEP) use among US women at risk of acquiring HIV. AIDS Patient Care and STDs,29(2), 102–110.
Baeten, J. M., Donnell, D., & Ndase, P. (2012). Antiretroviral prophylaxis for HIV prevention in heterosexual men and women. New England Journal of Medicine,367, 399–410.
Bazeley, P., & Jackson, K. (2013). Qualitative data analysis with NVivo. London: Sage Publications Limited.
Becher, M. (1974). The health belief model and personal health behavior. Health Education Monographs,2, 324–373.
Biello, K., Bazzi, A., Mimiaga, M., Biancarelli, D., Edeza, A., Salhaney, P., … Drainoni, M. (2018). Perspectives on HIV pre-exposure prophylaxis (PrEP) utilization and related intervention needs among people who inject drugs. Harm Reduction Journal,15(1), 55. https://doi.org/10.1186/s12954-018-0263-5.
Bourgois, P., Prince, B., & Moss, A. (2004). The everyday violence of hepatitis C among young women who inject drugs in San Francisco. Human Organization,63(3), 253–264.
Bryant, J., Brener, L., Hull, P., & Treloar, C. (2010). Needle sharing in regular sexual relationships: An examination of serodiscordance, drug using practices, and the gendered character of injecting. Drug and Alcohol Dependence,107(2–3), 182–187.
Bush, S., Magnuson, D., Rawlings, M., Hawkins, T., McCallister, S., & Mera Giler, R. (2016). Racial characteristics of FTC/TDF for pre-exposure prophylaxis (PrEP) users in the US. Paper presented at ASM Microbe 2016, Boston, MA.
Centers for Disease Control and Prevention. (2017). Preexposure prophylaxis for the prevention of HIV infection in the United States–2017 update. Retrieved January 5, 2017 from https://www.cdc.gov/hiv/pdf/risk/prep/cdc-hiv-prep-guidelines-2017.pdf.
Centers for Disease Control and Prevention. (2018). HIV surveillance report, 2017. Retrieved December 1, 2018 from http://www.cdc.gov/hiv/library/reports/hiv-surveillance.html.
Centers for Disease Control and Prevention. (2019). HIV in the United States and dependent areas. Retrieved September 15, 2019 from https://www.cdc.gov/hiv/statistics/overview/ataglance.html.
Chan, P. A., Glynn, T. R., Oldenburg, C. E., Montgomery, M. C., Robinette, A. E., Almonte, A., … Nunn, A. S. (2016). Implementation of preexposure prophylaxis for human immunodeficiency virus prevention among men who have sex with men at a New England sexually transmitted diseases clinic. Sexually Transmitted Diseases,43(11), 717–723.
Choopanya, K., Martin, M., & Suntharasamai, P. (2013). Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): A randomised, double-blind, placebo-controlled phase 3 trial. The Lancet,381, 2083–2090.
Cicero, T. J., Ellis, M. S., Surratt, H. L., & Kurtz, S. P. (2014). The changing face of heroin use in the United States: A retrospective analysis of the past 50 years. JAMA Psychiatry,71(7), 821–826.
Davey-Rothwell, M. A., & Latkin, C. A. (2007). Gender differences in social network influence among injection drug users: Perceived norms and needle sharing. Journal of Urban Health,84(5), 691–703.
Decker, M. R., Wirtz, A. L., Baral, S. D., Peryshkina, A., Mogilnyi, V., Weber, R. A., … Beyrer, C. (2012). Injection drug use, sexual risk, violence and STI/HIV among Moscow female sex workers. Sexually Transmitted Infections,88(4), 278–283.
El-Bassel, N., Shaw, S. A., Dasgupta, A., & Strathdee, S. A. (2014). People Who Inject Drugs in intimate relationships: It takes two to combat HIV. Current HIV/AIDS Reports,11(1), 45–51.
Escudero, D. J., Kerr, T., Wood, E., Nguyen, P., Lurie, M. N., Sued, O., & Marshall, B. D. L. (2015). Acceptability of HIV Pre-exposure Prophylaxis (PrEP) among people who inject drugs (PWID) in a Canadian setting. AIDS and Behavior,19(5), 752–757.
Felsher, M., Szep, Z., Krakower, D., Martinez-Donate, A., Tran, N., & Roth, A. M. (2018). “I don’t need PrEP right now”: A qualitative exploration of the barriers to PrEP care engagement through the application of the Health Belief Model. AIDS Education and Prevention,30(5), 369–381.
Galea, J. T., Kinsler, J. J., Salazar, X., Lee, S.-J., Giron, M., Sayles, J. N., … Cunningham, W. E. (2011). Acceptability of Pre-Exposure Prophylaxis (PrEP) as an HIV prevention strategy: Barriers and facilitators to PrEP uptake among at-risk Peruvian populations. International Journal of STD and AIDS,22(5), 256–262.
Gelberg, L., Andersen, R. M., & Leake, B. D. (2000). The behavioral model for vulnerable populations: application to medical care use and outcomes for homeless people. Health Services Research,34(6), 1273–1302.
Gowing, L., Ali, R., & White, J. M. (2017). Opioid antagonists with minimal sedation for opioid withdrawal. Cochrane Database of Systematic Reviews,5, CD002021. https://doi.org/10.1002/14651858.CD002021.pub4.
Grant, R. M., Lama, J. R., & Anderson, P. L. (2010). Preexposure chemoprophylaxis for HIV prevention in men who have sex with men. New England Journal of Medicine,363, 2587–2599.
Jones, C. M., Logan, J., Gladden, R. M., & Bohm, M. K. (2015). Vital signs: demographic and substance use trends among heroin users—United States, 2002–2013. Morbidity and Mortality Weekly Report,64(26), 719–725.
Kelesidis, T., & Landovitz, R. J. (2011). Preexposure prophylaxis for HIV prevention. Current HIV/AIDS Reports,8(2), 94–103.
Koechlin, F. M., Fonner, V. A., Dalglish, S. L., O’Reilly, K. R., Baggaley, R., Grant, R. M., … Kennedy, C. E. (2017). Values and preferences on the use of oral pre-exposure prophylaxis (PrEP) for HIV prevention among multiple populations: a systematic review of the literature. AIDS and Behavior,21(5), 1325–1335.
Miles, M. B., Huberman, A. M., & Saldana, J. (2013). Qualitative data analysis. Thousand Oaks, CA: Sage.
Mustanski, B., Johnson, A. K., Garofalo, R., Ryan, D., & Birkett, M. (2013). Perceived likelihood of using HIV pre-exposure prophylaxis medications among young men who have sex with men. AIDS and Behavior,17(6), 2173–2179.
Nyamathi, A. M., Lewis, C., Leake, B., Flaskerud, J., & Bennett, C. (1995). Barriers to condom use and needle cleaning among impoverished minority female injection drug users and partners of injection drug users. Public Health Reports,110(2), 166–172.
Philbin, M. M., Parker, C. M., Parker, R. G., Wilson, P. A., Garcia, J., & Hirsch, J. S. (2016). The promise of pre-exposure prophylaxis for black men who have sex with men: an ecological approach to attitudes, beliefs, and barriers. AIDS Patient Care STDs,30(6), 282–290.
Roth, A. M., Goldshear, J. L., Martinez-Donate, A. P., Welles, S., Chavis, M., & Van Der Pol, B. (2016). Reducing missed opportunities: Pairing sexually transmitted infection screening with syringe exchange services. Sexually Transmitted Diseases,43(11), 706–708.
Roth, A. M., Kral, A. H., Mitchell, A., Mukherjee, R., Davidson, P., & Lankenau, S. E. (2019). Overdose prevention site acceptability among residents and businesses surrounding a proposed site in Philadelphia, USA. Journal of Urban Health,96, 394–404.
Shrestha, R., & Copenhaver, M. (2018). Exploring the use of Pre-exposure Prophylaxis (PrEP) for HIV prevention among high-risk people who use drugs in treatment. Frontiers in Public Health,6, 195. https://doi.org/10.3389/fpubh.2018.00195.
Smith, D. K., Toledo, L., Smith, D. J., Adams, M. A., & Rothenberg, R. (2012). Attitudes and program preferences of African-American urban young adults about Pre-Exposure Prophylaxis (PrEP). AIDS Education and Prevention,24(5), 408–421.
Spinner, C. D., Boesecke, C., Zink, A., Jessen, H., Stellbrink, H.-J., Rockstroh, J. K., & Esser, S. (2016). HIV pre-exposure prophylaxis (PrEP): A review of current knowledge of oral systemic HIV PrEP in humans. Infection,44(2), 151–158.
Stein, J. A., Andersen, R., & Gelberg, L. (2007). Applying the Gelberg-Andersen behavioral model for vulnerable populations to health services utilization in homeless women. Journal of Health Psychology,12(5), 791–804.
Syvertsen, J. L., Robertson, A. M., Strathdee, S. A., Martinez, G., Rangel, M. G., & Wagner, K. D. (2014). Rethinking risk: Gender and injection drug-related HIV risk among female sex workers and their non-commercial partners along the Mexico–US border. International Journal of Drug Policy,25(5), 836–844.
Thigpen, M. C., Kebaabetswe, P. M., & Paxton, L. A. (2012). Antiretroviral preexposure prophylaxis for heterosexual HIV transmission in Botswana. New England Journal of Medicine,367, 423–434.
Tyler, K. A., & Wright, J. D. (2019). Homelessness and sexual assault. In W. T. O’Donohue & P. A. Schewe (Eds.), Handbook of sexual assault and sexual assault prevention (pp. 693–707). New York: Springer.
Ulin, P. R., Robinson, E. T., & Tolley, E. E. (2012). Qualitative methods in public health: A field guide for applied research. San Francisco: Wiley.
Worth, D. (1989). Sexual decision-making and AIDS: Why condom promotion among vulnerable women is likely to fail. Studies in Family Planning,20(6), 297–307.
Young, I., Flowers, P., & McDaid, L. M. (2014). Barriers to uptake and use of pre-exposure prophylaxis (PrEP) among communities most affected by HIV in the UK: findings from a qualitative study in Scotland. BMJ Open,4(11), 1–8. https://doi.org/10.1136/bmjopen-2014-005717
The authors thank the participants, Prevention Point Philadelphia especially former/current staff members: Jennie Coleman, Jade McKnight, Samantha Sitrin, Rose Lurano, Elby Katumkeeryil, and the dedicated research staff: Brogan Piecara, Bolutife Odeniyi, Brenna Aumaeir-Aredas, Dr. Annette Gadebeku, and Dr. Alicia Tucker.
This study was supported by the National Institute on Drug Abuse (1R21DA043417-01A1) and the American STD Association Developmental Award Program.
Study procedures were approved by the Drexel University Institutional Review Board (ID 1704005331) and the Prevention Point Philadelphia Executive Board.
Informed consent was obtained from all individual participants included in the studies.
Conflict of interest
The authors declare that they have no conflict of interest.
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
About this article
Cite this article
Felsher, M., Ziegler, E., Smith, L.R. et al. An Exploration of Pre-exposure Prophylaxis (PrEP) Initiation Among Women Who Inject Drugs. Arch Sex Behav 49, 2205–2212 (2020). https://doi.org/10.1007/s10508-020-01684-0
- Pre-exposure prophylaxis
- Women who inject drugs
- Health belief model